Market: NASD |
Currency: USD
Address: 1185 Avenue of the Americas
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Show more
📈 Oramed Pharmaceuticals Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$3.25
-
Upside/Downside from Analyst Target:
51.87%
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
100-200%
-
Upcoming Earnings Date:
2025-11-07
-
EPS Estimate:
-0.07
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Oramed Pharmaceuticals Inc.
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-08-14 | 0.31 |
| 2025-05-15 | -0.19 |
| 2025-03-27 | -0.26 |
| 2024-11-07 | -0.48 |
| 2024-08-14 | 0.22 |
| 2024-05-09 | 0.04 |
| 2024-03-06 | 0.33 |
| 2023-11-09 | -0.08 |
| 2023-08-10 | -0.03 |
| 2023-05-11 | -0.08 |
| 2023-03-06 | -0.22 |
| 2022-11-10 | -0.18 |
| 2022-08-10 | -0.27 |
| 2022-05-12 | -0.27 |
| 2021-07-14 | -0.17 |
| 2021-04-13 | -0.17 |
| 2021-01-14 | -0.23 |
| 2020-11-24 | -0.1 |
| 2020-07-07 | -0.1 |
| 2020-04-06 | -0.21 |
| 2020-01-09 | -0.15 |
| 2019-11-27 | -0.13 |
| 2019-07-10 | -0.23 |
| 2019-04-10 | -0.21 |
📰 Related News & Research
No related articles found for "oramed pharmaceuticals".
